Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Rallybio Corporation (RLYB : NSDQ)
 
 • Company Description   
Rallybio Corporation is a clinical-stage biotechnology company committed to identifying and accelerating the development of therapies for patients with severe and rare diseases. Rallybio Corporation is headquartered in New Haven, Connecticut.

Number of Employees: 35

 
 • Price / Volume Information   
Yesterday's Closing Price: $9.82 Daily Weekly Monthly
20 Day Moving Average: 44,843 shares
Shares Outstanding: 32.13 (millions)
Market Capitalization: $315.53 (millions)
Beta:
52 Week High: $25.78
52 Week Low: $6.74
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -6.83% 4.94%
12 Week -12.94% -4.29%
Year To Date 2.93% 25.77%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
234 CHURCH STREET SUITE 1020
-
NEW HAVEN,CT 06510
USA
ph: 203-859-3820
fax: -
investors@rallybio.com http://www.rallybio.com
 
 • General Corporate Information   
Officers
Martin W. Mackay - Chief Executive Officer and Director
Jeffrey M. Fryer - Chief Financial Officer and Treasurer
Helen M. Boudreau - Director
Rob Hopfner - Director
Ronald M. Hunt - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 75120L100
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 09/08/22
Share - Related Items
Shares Outstanding: 32.13
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $315.53 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.61 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.16 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 09/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.94
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -14.29%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -42.33
12/31/21 - -64.24
09/30/21 - -
ROA
03/31/22 - -28.99
12/31/21 - -37.90
09/30/21 - -
Current Ratio
03/31/22 - 28.93
12/31/21 - 27.61
09/30/21 - 26.20
Quick Ratio
03/31/22 - 28.93
12/31/21 - 27.61
09/30/21 - 26.20
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 5.07
12/31/21 - 5.47
09/30/21 - 5.80
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©